Navigation Links
Device aims to decrease wait period for patients needing immunotherapy
Date:2/13/2009

HOUSTON - Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have created a device that significantly decreases the time needed to produce genetically manipulated T cells in preclinical tests for leukemia.

Paul (Yoonsu) Choi, Ph.D., presented the device he engineered, along with supporting research, at the annual meeting of the American Society for Blood and Marrow Transplantation in Tampa, FL, today. Choi's device, called HitMeD (high throughput medical electroporation device), has been used for preclinical studies in treatment of acute lymphocytic leukemia (ALL), with early results indicating it has the potential to decrease a patient's wait time to receive immunotherapy from weeks and months to days and weeks.

"This particular device is an automated system designed to work with the press of a button, which saves us time and resources," says Choi. "More importantly, it's a very safe method of gene transfer."

Multiple relapsed ALL in pediatric patients is a rapidly progressive cancer that is often resistant to chemotherapy, leading to poor survival prognosis. Since chemotherapy typically fails these patients, new approaches, such as cell-based therapy, are needed to combat the quickly spreading leukemia.

Choi, along with senior researcher Laurence Cooper, M.D., Ph.D., from the Children's Cancer Hospital, are studying ways to genetically manipulate T cells, an important component of a person's immune system, to specifically attack tumor cells while keeping risk to the patient at a minimum.

One method found to be effective in preclinical tests is taking a sample of human T cells, increasing their number through stimulation and then genetically transferring desired messenger RNA (mRNA) into the T cells. The mRNA, once inside the T cells, produces a protein called chimeric antigen receptor (CAR), which allows the T cells to recognize and specifically kill tumor cells. The HitMeD device carries out this entire process. Once the altered T cells are created, researchers use them to battle leukemia cells in the laboratory.

Although these manipulated T cells have shown to be effective against ALL in mice and cell lines, they lose their fighting power after a few days. For this reason, researchers engineered the new HitMeD, which processes the T cells 100 times faster than the current standard commercial technologies.

"Our goal is to provide therapy to patients closer to their time of need," says Cooper. "The HitMeD processes a larger volume of T cells in a continuous fashion over a much shorter time than we can achieve with commercial devices. We hope that will translate to better treatment opportunities for relapsed patients."

Cooper and researchers are planning a Phase I trial that could open this year. This trial would allow multiple-relapsed ALL patients to receive manipulated T cells that have been processed by HitMeD. These special T cells will act like an army of antibodies rushing in to attack tumor cells, but quickly retreating after their ammunition is used. With HitMeD, doctors hope to infuse additional doses of T cells more rapidly to sustain the fight until the patient can receive additional treatment, such as a stem cell transplant.


'/>"/>

Contact: Sara Farris
sfarris@mdanderson.org
713-792-9133
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Related medicine news :

1. MSU engineering team designs innovative medical device
2. New AnyTrack GPS Devices Track Assets Indoors, Outdoors or Hidden
3. Implantable device designed to detect, stop seizures under study at MCG
4. Visiprise Launches Podcast Series with AMR to Support Medical Device Manufacturers
5. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
6. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
7. New Device for Clearing Blocked Arteries in the Legs Receives FDA Clearance for Peripheral Use - Procedures Performed Across the US Within First 48 Hours
8. Mobility-enhancing device developed at University of Alberta will receive prestigious da Vinci Award
9. Design Resource Extends Support for Orthopaedic and Cardiovascular Devices
10. FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use
11. FDA approves knee-injury device for humans
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Device aims to decrease wait period for patients needing immunotherapy
(Date:3/23/2017)... , ... March 23, 2017 , ... The physicians of ... in the greater Houston Area. The new location is located at 2255 E. Mossy ... in Springwoods Village. This newest location will provide patients living in the north Houston ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy Specialists (TexPTS) ... Gruene Road in Building 2. The clinic is the group’s second in New Braunfels ... opening the company’s second New Braunfels location brings things full circle for the group, ...
(Date:3/23/2017)... ... ... The IoT (Internet of Things) is revolutionizing the way the world operates. ... individual consumers alike. Laboratories can maximize their profit margin by increasing throughput. ... to $11 trillion dollars by the year 2025. McKinsey expects the IoT to have ...
(Date:3/23/2017)... ... ... are unaware of the dangers that infectious bacteria play in mouth disease, while 1 out ... that dentists recommend. The ramifications of improper oral upkeep go far beyond bad breath and ... hours of work each year due to dental issues. That is why Mediaplanet is proud ...
(Date:3/23/2017)... ... ... March is National Kidney Month – the perfect time to pause and ... health. Every day, two kidneys filter about 120 to 150 quarts of blood. Put ... waste, regulating fluid levels and blood pressure, supporting bone health and promoting red blood ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... Newborns are highly vulnerable to infections ... their young immune systems typically mount weak antibody ... achieving strong vaccine responses in newborn animals, including ... trials — by adding compounds known as adjuvants ... papers, they also describe improved adjuvant formulations that ...
(Date:3/23/2017)... , March 23, 2017 /PRNewswire/ - INVICTUS MD STRATEGIES ... FRA: 8IS) Invictus MD announces that AB Laboratories Inc. ... its licensed production facility under the Access to Cannabis ... Hamilton, Ontario . The facility, ... October 2016, is currently operating at half capacity, with ...
(Date:3/23/2017)... , March 23, 2017 ... Composite ended the trading session at 5,821.64, up ... lower, to finish at 20,661.30; and the S&P ... were broad based as six out of nine ... Stock-Callers.com has initiated reports coverage on the following ...
Breaking Medicine Technology: